A guide to the organ-on-a-chip
Abstract Organs-on-chips (OoCs) are systems containing engineered or natural miniature
tissues grown inside microfluidic chips. To better mimic human physiology, the chips are …
tissues grown inside microfluidic chips. To better mimic human physiology, the chips are …
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …
worldwide. With no Food and Drug Administration approved drugs, current treatment options …
Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world.
High levels of free fatty acids in the liver impair hepatic lysosomal acidification and reduce …
High levels of free fatty acids in the liver impair hepatic lysosomal acidification and reduce …
Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and
parallels comorbidities such as obesity, metabolic syndrome, dyslipidemia, and diabetes …
parallels comorbidities such as obesity, metabolic syndrome, dyslipidemia, and diabetes …
Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies?
A Di Ciaula, S Passarella, H Shanmugam… - International Journal of …, 2021 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and
represents the hepatic expression of several metabolic abnormalities of high epidemiologic …
represents the hepatic expression of several metabolic abnormalities of high epidemiologic …
In vitro and in vivo models of non-alcoholic fatty liver disease: a critical appraisal
PA Soret, J Magusto, C Housset… - Journal of clinical medicine, 2020 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic fatty liver (NAFL) and non-
alcoholic steatohepatitis (NASH), represents the hepatic manifestation of obesity and …
alcoholic steatohepatitis (NASH), represents the hepatic manifestation of obesity and …
[HTML][HTML] Organoids to model liver disease
S Nuciforo, MH Heim - JHEP Reports, 2021 - Elsevier
The organoid model represents a major breakthrough in cell biology that has revolutionised
biomedical research. Organoids are 3D physiological in vitro structures that recapitulate …
biomedical research. Organoids are 3D physiological in vitro structures that recapitulate …
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
Non-alcoholic fatty liver disease (NAFLD) represents a global healthcare challenge,
affecting 1 in 4 adults, and death rates are predicted to rise inexorably. The progressive form …
affecting 1 in 4 adults, and death rates are predicted to rise inexorably. The progressive form …
Liver organoids: recent developments, limitations and potential
Liver cell types derived from induced pluripotent stem cells (iPSCs) share the potential to
investigate development, toxicity, as well as genetic and infectious disease in ways currently …
investigate development, toxicity, as well as genetic and infectious disease in ways currently …
Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system
Interactions between adipose tissue, liver and immune system are at the center of metabolic
dysfunction-associated steatotic liver disease and type 2 diabetes. To address the need for …
dysfunction-associated steatotic liver disease and type 2 diabetes. To address the need for …